CLICK HERE to watch the recorded webinar
Blended Learning Journey on Diabetes and Pre-diabetes 2024
Hyperglycemia, pre-diabetes and undiagnosed type 2 diabetes mellitus are growing global health problems. Although people can live with hyperglycemia without overt symptoms, it increases the risk of developing serious health conditions and for premature death. Hyperglycemia in prediabetes and type 2 diabetes is reversible if the patient is able and willing to adopt lifestyle recommendations. Screening at-risk populations is crucial for providing affected individuals with information and help that reduces, or prevents, escalation of their condition. Screening, preventative and best practice care and personalization of treatment are also important for diabetic-related foot disease. The current lifetime risk of diabetic foot ulcer for those with diabetes is 19–34 and the 5-year mortality rate is 50–70% (McDermott, 2023). The amputation incidence is increasing particularly in the young and in racial and ethnic minority populations; all statistics are strongly linked to poor diabetes management (McDermott, 2023). Screening and care for women of child-bearing age with diabetes, especially during pre-pregnancy and pregnancy, is a widening practice gap, as is the ongoing care of women who experience diabetes during pregnancy and who are then at increased risk of developing diabetes in later life.
At the end of the blended learning journey, participants will be able to:
Clinicians involved in endocrinology, particularly diabetes, pre-diabetes; fertility and pregnancy management, obesity management and general practice; some content of interest to midwives and nurses involved in pre-natal and post-natal care; some content of interest to vascular specialists and podiatrists.
The official language of this educational programme will be English. Simultaneous translation into Spanish and Chinese will be provided.
The BLENDED LEARNING JOURNEY ON DIABETES AND PRE-DIABETES 2024 will be submitted for CME accreditation from the European Accreditation Council for Continuing Medical Education (EACCME), and/ or the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and for Continuing Professional Development (CPD) credits.
Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.
Raffaella Buzzetti is Professor of Endocrinology at the Department of Experimental Medicine, Sapienza University of Rome and has been leading the Diabetes Unit at Policlinico Umberto I Hospital since 2017, where she provides integrated care for diabetes and metabolic diseases. Beside her clinical activity, Professor Buzzetti coordinates the II semester of the IV year in Medicine and Surgery at Sapienza University, while lecturing on courses of “Integrated pathology III” and “Medical-Scientific Methodology VIII”. Professor Buzzetti graduated in Medicine and Surgery, where she specialized in “Endocrinology” and “Medical Genetics” at Sapienza, University of Rome and was a Research Fellow at Queen Mary College, St. Bartholomew’s Hospital, London. Professor Buzzetti’s research interests include genetic susceptibility to polygenic diseases such as type 1 diabetes, pathogenesis and clinical features of type I diabetes and adult-onset autoimmune diabetes; she is clinical lead for phase II and III studies. She has authored and co-authored 284 publications (H. Index Scopus 53), with 78 of them in the last 3 years. Professor Buzzetti is a member of the editorial boards for Diabetes Metabolism Research and Reviews, PLOS ONE and is also a member of the board of the National Committee of Medical Research Evaluators.
Antonio Ceriello is Research Consultant at IRCCS MultiMedica, Milan, Italy, Adjunt Professor of Internal Medicine at Luigi Vanvitelli University of Naples, Italy and Guang Ci Professor at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China. Professor Ceriello has published widely in the area of diabetes with over 500 original papers and with an h-index of 110 (SCOPUS). He chaired the International Diabetes Federation (IDF) committee for the development in 2008, and in the 2011 for the update of “Guideline for Management of Postmeal Glucose ”. Currently, is the President of the European Association for the Study of Diabetes (EASD) Study Group on “Diabetes and Cardiovascular Diseases”. He also served as Board member of the “2019 European Society of Cardiology (ESC) guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD “. He also served as Associate Editor of “Diabetes Care” from 2003 to 2011 and Associate Editor of “Diabetic Medicine” from 2005 to 2016. From July 1st 2016 he has been appointed as Editor in Chief of “Diabetes Research and Clinical Practice”, the official IDF journal. Prof. Ceriello has also been appointed by IDF as Co-Chairman for the development of the “2025 Global Clinical Practice Recommendations for the Management of Type 2 Diabetes” and as Chairman for the 2025 IDF World Congress, in 2025 by EASD as Member of the Committee on Clinical Affairs (CCA) for 2025-2028 and delegate as representative of EASD at European Medical Agency (EMA). Prof. Ceriello is the winner of the 2004 “Camillo Golgi Prize” of the EASD, of the 2017 of the “Hellmut Mehnert Award”, during the IDF 2017 Meeting, in the 2022 of the “Aretaeus Lecture Award” from the Hellenic Society of Diabetology, in 2023 of the “Somogyi Award” from the Hungarian Diabetes Association and in of the 2024 “Shaukat Sadikot Oration” at Diabetes India Congress.
Osama Hamdy, MD, PhD is a world expert and recognized thought leader in obesity, nutrition, and diabetes technology. Dr. Hamdy is a senior endocrinologist and Medical Director of the Joslin Obesity Clinical Program and Director of the International Medical Affairs at Joslin Diabetes Center, and Associate Professor of Medicine at Harvard Medical School. Dr. Hamdy is very active in nutrition and obesity clinical research. His lab led to many innovations and discoveries that changed how we currently manage obesity in patients with either type 2 or type 1 diabetes and were incorporated in National and International Guidelines. Dr. Hamdy research led to the first landmark discovery that 7% weight loss in obese patients with and without diabetes significantly improve vascular endothelial function, insulin sensitivity and markers of inflammation. Dr. Hamdy was a co-investigator in two US landmark studies: the “Diabetes Prevention Program” and “the Look AHEAD Study”. In 2005, Dr. Hamdy founded the “Weight Achievement and Intensive Treatment (Why WAIT) program, which is currently implemented nationally and internationally. He also found the Diabetes Remission Outcome Program (DROP) that helped newly diagnosed patients with diabetes within 5 years to get remission from the disease and stop medications. Dr. Hamdy co-chaired the task force that developed the global transcultural Diabetes Nutrition Algorithm (tDNA). Dr. Hamdy long-term work on diabetes technology including AID, CGMs, and AI ranked him the world’s 3rd most cited physician on diabetes technology. Dr. Hamdy joined Joslin Diabetes Center in 1998, where he founded the obesity clinical program and restructured the inpatient diabetes program. Dr. Hamdy won the 2015 Michaela Modan Award of the American Diabetes Association for his research on long-term diabetes weight management. He was given the Compassionate Caregiver Award of the Kenneth Schwartz Center. Dr. Hamdy has more than 150 peer-reviewed original articles, reviews, and book chapters. He is also the author of the Harvard Health Publication “The Diabetes Breakthrough” reversing diabetes through weight management. He is on the editorial review board of many medical journals including Lancet, JAMA, British Medical Journal, Diabetes Care and 2 times section editor of Nutrients and Current Diabetes Report and also associate editor of Frontiers in Nutrition. |
Ernesto Maddaloni, MD, PhD, currently holds the position of Associate Professor of Endocrinology and Metabolic Disease at the Department of Experimental Medicine, Unit of Diabetes, Sapienza University of Rome. He also holds international collaborations, as a past fellow of the Joslin Diabetes Center (Harvard Medical School, Boston, MA, USA), and holding a position as Research Associate at the Diabetes Trial Unit, University of Oxford, UK, which he joined in in 2017 as a mentee of the European Foundation for the Study of Diabetes (EFSD) Future Leaders Mentorship Program. Dr Maddaloni actively pursue studies on clinical diabetes, cardiovascular outcomes and novel diabetes complications. His research interests focus on the study of adults with autoimmune diabetes and the interplay between vascular complications, bone health and autoimmunity. Dr Maddaloni has been a study investigator and coordinator for several national and international clinical trials and has published as lead author in several top-ranked peer-reviewed international medical journals (for publication list see: https://www.ncbi.nlm.nih.gov/myncbi/1xGOuoCbV1uAs/bibliography/public/). His scientific achievements have been recognized with several awards, including the 2015 Albert Renold Fellowship from the European Foundation for the Study of Diabetes, the 2017 (under 32) and 2021 (under 35) Young Investigator Awards from the Italian Society of Endocrinology (SIE), the 2017 Early Investigator Award from the Endocrine Society (USA) and the 2020 Young (under 35) Investigator Award and the Alcmeone award from the Italian Society of Diabetes (SID).
Currently serving as Professor of the Department of Biochemistry and Molecular Biology at the University of the Philippines College of Medicine, and a Clinical Professor at the Division of Endocrinology, Diabetes and Metabolism of the Department of Medicine at the Philippine General Hospital, Dr Nemencio Nicodemus Jr. is also Vice Chair for Postgraduate Training and the departmental training officer. Nationally, Prof. Nicodemus is the Treasurer of the Philippine College of Physicians, President of the Philippine Association for the Study of Overweight and Obesity (PASOO) and a past President of the Philippine Thyroid Association and the Philippine Society of Endocrinology, Diabetes and Metabolism. An active and engaging lecturer, Dr Nicodemus has been invited to several regional and international conferences, including the International Society of Endocrinology, International Diabetes Federation and ASEAN Federation of Endocrine Societies as a resource speaker. Prof. Nicodemus has published several articles and book chapters on diabetes, thyroid and obesity. He is a member of the technical committee who oversee clinical practice guidelines on diabetes in pregnancy and thyroid disorders in pregnancy, including guidelines on recurrent pregnancy loss in the Philippines.
Alberto Piaggesi graduated in Medicine and Surgery at the Medical School, University of Pisa where he then specialized both in Internal Medicine and Endocrinology and Metabolism. Since 1991, he has held a post of Consultant at the Department of Endocrinology and Metabolism, University of Pisa, where he is the Director of the Diabetic Foot Section, a tertiary referral center for Tuscany and Central Italy. He is Professor of Endocrinology and Metabolism at the Medical and Podiatry School, and Professor of Lower Limb Complications Management at the School of Specialization in Endocrinology and Metabolism, University of Pisa. He has authored more than 100 publications, books and book chapters on many aspects of the diabetic foot. He serves as a referee for peer-review international journals, and he is a member of the editorial board for the International Consensus Guidelines for the Management of the Diabetic Foot. Prof. Piaggesi served as Scientific Member and then President of the European Wound Management Association (EWMA) and he was a founder of the International Association of Diabetic Foot Surgeons (i-ADFS). He is the scientific lead responsible for the organization of the Italian and the International Residential Course on the Management of Lower Limb Complications of Diabetes and he has trained over 1000 diabetologists, podiatrists, nurses and orthotists during his 25-year tenure.
Stay in the know with our CME updates
